Key statistics
On Monday, Fulcrum Therapeutics Inc (FULC:NMQ) closed at 7.81, 237.37% above the 52 week low of 2.32 set on Apr 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 8.17 |
|---|---|
| High | 8.26 |
| Low | 7.52 |
| Bid | 7.50 |
| Offer | 7.81 |
| Previous close | 8.38 |
| Average volume | 1.62m |
|---|---|
| Shares outstanding | 66.60m |
| Free float | 65.84m |
| P/E (TTM) | -- |
| Market cap | 558.11m USD |
| EPS (TTM) | -1.18 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
- Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
- Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
- Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
- Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
More ▼
